UroGen Pharma Ltd. (URGN)

UroGen Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	623	463	205	213	398	700
Market Cap Growth	136.31%	126.06%	-3.94%	-46.44%	-43.13%	18.23%
Enterprise Value	556	425	203	123	296	555
PE Ratio	-	-4.53	-1.87	-1.92	-3.10	-6.66
PS Ratio	7.39	5.60	3.18	4.44	33.74	38893.81
PB Ratio	-12.75	-7.10	-2.29	25.34	4.13	3.88
P/FCF Ratio	-6.21	-6.05	-2.33	-2.49	-3.72	-9.81
P/OCF Ratio	-6.22	-6.06	-2.34	-2.51	-3.76	-9.86
EV/Sales Ratio	6.60	5.13	3.16	2.57	25.12	30838.48
EV/EBITDA Ratio	-5.23	-5.18	-2.08	-1.15	-2.41	-5.35
EV/EBIT Ratio	-5.13	-5.08	-2.04	-1.13	-2.37	-5.28
EV/FCF Ratio	-5.40	-5.55	-2.31	-1.44	-2.77	-7.78
Debt / Equity Ratio	-2.45	-1.52	-1.11	0.05	0.02	0.01
Debt / EBITDA Ratio	-1.15	-1.21	-1.01	0.00	-0.01	-0.03
Debt / FCF Ratio	-1.19	-1.30	-1.13	0.00	-0.01	-0.04
Quick Ratio	6.80	4.91	4.74	4.56	5.15	7.58
Current Ratio	7.47	5.42	5.39	5.11	5.39	7.63
Asset Turnover	0.51	0.57	0.45	0.38	0.08	0
Interest Coverage	-6.37	-5.68	-11.80	-	-	-
Return on Equity (ROE)	146.00%	112.90%	208.50%	-256.70%	-100.80%	-49.20%
Return on Assets (ROA)	-62.50%	-70.50%	-76.20%	-87.70%	-87.10%	-45.70%
Return on Capital (ROIC)	-119.17%	-191.72%	-809.68%	-1047.46%	-129.52%	-59.85%
Earnings Yield	-16.75%	-22.08%	-53.60%	-51.98%	-32.27%	-15.02%
FCF Yield	-13.24%	-16.54%	-42.88%	-40.17%	-26.90%	-10.19%
Buyback Yield / Dilution	-43.38%	-26.43%	-2.06%	-2.60%	-6.10%	-30.31%
Total Shareholder Return	-43.38%	-26.43%	-2.06%	-2.60%	-6.10%	-30.31%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).